Formoterol vs short‐acting beta2‐agonist
Fatal serious adverse events · people with asthma
Formoterol showed no clear difference in fatal serious adverse events (all‐cause) compared with short‐acting beta2‐agonist (low certainty).
1 finding from 1 review
- Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma 2010 · Cochrane Headline outcomes onlyOR 1.08 [0.51, 2.3]5 studies · 21629 participantsLow